KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.

Blood · 2026-Mar-12 · PMID 41385341

Panel C提取完成待 EXE 对齐验证

OS

Figure 2. Survival probabilities and the cumulative incidence of primary and secondary end point events. (A) The cGFS (the primary end point) after Orca-T or Tac/MTX prophylaxis over 1 year. The shaded areas indicate 95% simultaneous confidence bands. (B) The cumulative incidence of moderate-to-severe cGVHD over 1 year. (C) The OS probability over 1 year. (D) The survival free from grade 3 to 4 acute GVHD, moderate-to-severe cGVHD, or relapse (GRFS) over 1 year. For the estimates of the secondary end point events, 95% CIs for survival and cumulative incidence at 1 year (panels B-D) are provided, but they have not been adjusted for multiplicity and should not be used for hypothesis testing.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.74
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:16:29+00:00